ChartMill assigns a Buy % Consensus number of 77% to NMRA. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2026-01-12 | Leerink Partners | Initiate | Outperform |
| 2025-12-01 | RBC Capital | Upgrade | Sector Perform -> Outperform |
| 2025-11-17 | Stifel | Maintains | Hold -> Hold |
| 2025-10-28 | Needham | Maintains | Buy -> Buy |
| 2025-10-27 | Guggenheim | Upgrade | Neutral -> Buy |
| 2025-09-16 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2025-07-16 | Mizuho | Maintains | Outperform -> Outperform |
| 2025-05-13 | Needham | Reiterate | Buy -> Buy |
| 2025-04-10 | Needham | Reiterate | Buy -> Buy |
| 2025-04-02 | B of A Securities | Downgrade | Buy -> Underperform |
| 2025-03-10 | Guggenheim | Downgrade | Buy -> Neutral |
| 2025-03-07 | Stifel | Downgrade | Buy -> Hold |
| 2025-03-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-04 | Needham | Reiterate | Buy -> Buy |
| 2025-03-04 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-03-04 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-06 | B of A Securities | Maintains | Buy -> Buy |
| 2025-01-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-02 | Needham | Reiterate | Buy -> Buy |
| 2024-12-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-13 | Needham | Reiterate | Buy -> Buy |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-05 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2024-10-18 | Needham | Reiterate | Buy -> Buy |
| 2024-10-01 | HC Wainwright & Co. | Initiate | Buy |
| 2024-09-12 | Needham | Reiterate | Buy -> Buy |
| 2024-09-04 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-07 | Needham | Reiterate | Buy -> Buy |
14 analysts have analysed NMRA and the average price target is 9.33 USD. This implies a price increase of 389.54% is expected in the next year compared to the current price of 1.905.
The consensus rating for NEUMORA THERAPEUTICS INC (NMRA) is 77.1429 / 100 . This indicates that analysts generally have a positive outlook on the stock.
The number of analysts covering NEUMORA THERAPEUTICS INC (NMRA) is 14.